Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
28 Mar 24
DEFA14A
Additional proxy soliciting materials
28 Mar 24
DEF 14A
Definitive proxy
28 Mar 24
8-K
Departure of Directors or Certain Officers
18 Mar 24
PRE 14A
Preliminary proxy
18 Mar 24
8-K
Strengthening Neuroscience Portfolio
18 Mar 24
SC TO-T/A
Third party tender offer statement (amended)
23 Feb 24
8-K
Other Events
22 Feb 24
424B5
Prospectus supplement for primary offering
16 Feb 24
SC TO-T/A
Third party tender offer statement (amended)
16 Feb 24
8-K
Departure of Directors or Certain Officers
15 Feb 24
FWP
Free writing prospectus
14 Feb 24
8-K
Bristol Myers Squibb Recommends Stockholders Reject “Mini-Tender” Offer by Tutanota LLC
14 Feb 24
10-K
2023 FY
Annual report
13 Feb 24
424B2
Prospectus for primary offering
13 Feb 24
SC TO-T/A
Third party tender offer statement (amended)
12 Feb 24
8-K
Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2023
2 Feb 24
SC TO-T
Third party tender offer statement
25 Jan 24
8-K
Regulation FD Disclosure
8 Jan 24
SC TO-C
Information about tender offer
26 Dec 23
DFAN14A
Additional proxy materials by non-management
22 Dec 23
DFAN14A
Additional proxy materials by non-management
22 Dec 23
8-K
Bristol Myers Squibb Strengthens Neuroscience Portfolio with Acquisition of Karuna Therapeutics
22 Dec 23
8-K
Other Events
13 Nov 23
424B5
Prospectus supplement for primary offering
1 Nov 23
8-K/A
Departure of Directors or Certain Officers
31 Oct 23
FWP
Free writing prospectus
30 Oct 23
424B3
Prospectus supplement
30 Oct 23
10-Q
2023 Q3
Quarterly report
26 Oct 23
8-K
Bristol Myers Squibb Reports Third Quarter Financial Results for 2023
26 Oct 23
DFAN14A
Additional proxy materials by non-management
10 Oct 23
8-K
Other Events
10 Aug 23
10-Q
2023 Q2
Quarterly report
27 Jul 23
8-K
Bristol Myers Squibb Reports Second Quarter Financial Results for 2023
27 Jul 23
8-K
Departure of Directors or Certain Officers
4 May 23
10-Q
2023 Q1
Quarterly report
27 Apr 23
8-K
Bristol Myers Squibb Reports First Quarter Financial Results for 2023
27 Apr 23
DEFA14A
Additional proxy soliciting materials
26 Apr 23
8-K
Bristol Myers Squibb Announces Leadership Transition Plan
26 Apr 23
DEFA14A
Additional proxy soliciting materials
10 Apr 23
Latest ownership filings
4
Karin Shanahan
2 Apr 24
4
PHYLLIS R YALE
2 Apr 24
4
Gerald L Storch
2 Apr 24
4
Theodore R. Samuels II
2 Apr 24
4
Derica W Rice
2 Apr 24
4
Deepak Bhatt
2 Apr 24
4
Peter J Arduini
2 Apr 24
4
Adam Lenkowsky
12 Mar 24
4
SANDRA LEUNG
12 Mar 24
4
Robert M Plenge
12 Mar 24
4
Ahn Amanda Poole
12 Mar 24
4
Samit Hirawat
12 Mar 24
4
Phil M Holzer
12 Mar 24
4
Lynelle Hoch
12 Mar 24
4
Cari Gallman
12 Mar 24
4
CHRISTOPHER S. BOERNER
12 Mar 24
4
Karin Shanahan
12 Mar 24
4
Gregory Scott Meyers
12 Mar 24
4
Benjamin Hickey
12 Mar 24
4
David V Elkins
12 Mar 24
4
Giovanni Caforio
12 Mar 24
4
Benjamin Hickey
4 Mar 24
3
Benjamin Hickey
4 Mar 24
3
Phil M Holzer
23 Feb 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
4
PHYLLIS R YALE
5 Feb 24
4
Gerald L Storch
5 Feb 24
4
Karen H Vousden
5 Feb 24
4
Theodore R. Samuels II
5 Feb 24
4
Derica W Rice
5 Feb 24
4
Paula A Price
5 Feb 24
4
Medina Manuel Hidalgo
5 Feb 24
4
Julia A Haller
5 Feb 24
4
Deepak Bhatt
5 Feb 24
4
Peter J Arduini
5 Feb 24
4
Gregory Scott Meyers
5 Feb 24
SC 13G/A
BlackRock Inc.
25 Jan 24
3
Ahn Amanda Poole
3 Jan 24
4
PHYLLIS R YALE
3 Jan 24
4
Gerald L Storch
3 Jan 24